


FOUR TECHNOLOGY PILLARS



In Clinical Studies

ModifEye™

Tear-based precision medicine for retinal diseases



The Problem

- Retinal care is reactive — no way to predict AMD deterioration or match therapies
- Urgent need for novel therapies

Our Solution

- Tear catalytic signatures as biomarkers and drug targets
- Harvard-licensed platform; US provisional patent pending
- Differentiated healthy eyes vs. AMD types and stages
- Target pharma partners: Roche, Regeneron, Biogen, Astellas

>\$17B

AMD/DME treatment market

>220M

AMD/DME patients globally

ModifEye is currently 100% owned by BioLight. A definitive share exchange agreement with DiagnosTear Technologies Inc. has not yet been executed.

CE-IVD · Commercialization

TeaRx™ Dry Eye

Multi-parametric dry eye point-of-care testing platform



The Problem

- Dry eye (DED) is ~1/3 of all US ophthalmology complaints
- DED subtypes need different treatments, but no single test tells them apart

Our Solution

- Proprietary tear collector, multi-parametric panel, cloud algorithm
- 86% sensitivity, 87% specificity. Differentiates severe vs. non-severe
- Detects MGD and predicts responsiveness to Cyclosporin A
- Patented, CE-cleared and ready for commercialization

344M

Patients globally / yr

\$0.75B

TAM for DED diagnostics

In Clinical Validation towards FDA

TeaRx™ Red Eye

Differential red eye diagnostics (viral vs. allergic)



The Problem

- Red eye: >1% of primary care visits; GPs can't identify the cause
- Herpes rules out steroids, so GPs refer to ophthalmologists

Our Solution

- World's first triple-differential POCT: adenoviral, herpetic, allergic
- First point-of-care test for herpes; patented assay device
- Run by a nurse or technician in GP, ER and pediatric settings
- Clinically validated; FDA 510(k)/CLIA pre-sub filed Sep 2026

20M

US adenoviral cases/yr

6M

US ocular allergy/yr

500K

US herpes cases/yr

Seed Stage / Alpha Dev.

Clarify™

Non-invasive eye imaging for rapid, on-site hematology



The Problem

- Blood testing remains invasive, slow and labor-intensive
- Central labs, consumables and staff drive high costs and delays

Our Solution

- Blood insights from a simple eye scan — AI results in seconds
- No needles, no lab, no complex logistics, no consumables
- Expands to new biomarkers through software alone
- 224-patient validation (Hb, RBC) published in npj Digital Medicine

\$56B

Global blood testing TAM

\$8B

Global PoC CBC market

Investment Highlights

- ✓ **Four platforms** addressing >1B patients
- ✓ **U.S. catalyst:** TeaRx™ Red Eye on FDA 510(k)/CLIA waiver path
- ✓ **Pipeline upside:** ModifEye™ (retina) and Clarify™ (blood testing)
- ✓ **Protected technology:** proprietary tear Dx + AI interpretation
- ✓ **Public-market platform:** CSE & Frankfurt listed; BioLight anchor shareholder; potential NASDAQ uplisting*

*Subject to meeting applicable listing requirements

Use of Proceeds

CAPITAL SOUGHT
US\$8–12M

TeaRx™ Red Eye FDA 510(k) / CLIA waiver clinical trials	\$3.0M
ModifEye™ Clinical studies + POCT prototype (AMD/DME)	\$2.5M
Clarify™ — Alpha Device Month 16 milestone	\$2.5M
TeaRx™ Dry Eye Global commercialization	\$0.5M
Corporate, IP & Working Capital	\$1.5M

Key Milestones

- **Apr 2024** Positive final results: 600-patient TeaRx™ Dry Eye study (India)
- **Dec 2024** CSE listing (DTR) & ~\$3.5M CAD financing
- **Mar 2025** Red Eye production mold; first 1,000 devices manufactured
- **Aug 2025** ModifEye pivotal results: clear differentiation between AMD types
- **Oct 2025** Listed on the Frankfurt Stock Exchange (FSE: X8F)
- **May 2026** TeaRx™ Dry Eye 600-subject study published in Curr. Eye Res.
- **May 2026** Clarify exclusive license with Sheba MC / Tel Aviv University
- **Sep 2026** Red Eye FDA 510(k) / CLIA waiver pre-submission

LEADERSHIP TEAM



Yaacov Michlin Chairman of the Board

CEO BioLight (TASE: BOLT) · Co-Chair IATI · Ex CEO BrainsWay (NASDAQ IPO) · Ex CEO Yissum



Dr. Shimon Gross Chief Executive Officer

>25 yrs IVD · Ex VP Genomics, AID Genomics · Ex VP Sales, Savyon Diagnostics · 25+ patents/publications



Dr. Hila Barash VP Research & Development

>20 yrs diagnostics R&D · Ex R&D Mgr at AID Genomics & Sheba MC · Researcher Emendo, Hadassah MC



Yifftach Biel Chief Financial Officer

CFO BioLight (TASE: BOLT) · Ex Delek Global Real Estate (AIM: DGRE) · Certified CPA



Avital Beck Business Development Manager

Ex CEO Wilk (TASE: WILK) · Founder and CEO – DiagnoseStick Ltd · Founder and CEO - STAR-t-UP · Ex QA Manager - Kadimastem (TASE: KDST)

SCIENTIFIC AND CLINICAL ADVISORS



Prof. Anat Loewenstein

Tel Aviv Sourasky Medical Center



Prof. Yifat Merbl

The Weizmann Institute of Science



Prof. Sayan Basu

LV Prasad Eye Institute



Prof. Yigal Rotenstreich

Sheba Medical Center



Prof. Haim Suchowski

Tel Aviv University



Dr. Carl D. Regillo

Thomas Jefferson University



Prof. David S. Boyer

Retina-Vitreous Associates Medical Group and Cedars Sinai



Prof. Itay Chowers

Hadassah Medical Center



Susan Benton, MBA

i2eye Consulting

ISRAELI & GLOBAL INNOVATION HUBS

Israel Innovation Authority: 2 grants awarded, 1 pending
Collaborators: Weizmann, Tel Aviv Univ., Harvard, AlyaTec, Lexitas
Clinical network: Clalit, Leumit & Maccabi HMOs; Sheba, Kaplan, Shaare Zedek, Sourasky, Hadassah, Soroka Medical Centers; LV Prasad Eye Inst. (India)

CANADA — CAPITAL & GOVERNANCE

Listed: CSE (Dec 2024) & Frankfurt (Oct 2025); full SEDAR+ disclosure
Governance: Canadian CPA board member (John Sinclair, Baker Tilly WM LLP)
Anchor shareholders: BioLight (TASE: BOLT) and Elcam Medical

To arrange a discussion or request further information:

Email: john.sinclair@diagnostear.com

Web: www.diagnostear.com | ir@diagnostear.com

Listed: CSE: DTR | Frankfurt: X8F | SEDAR+: sedarplus.ca

We are engaging with a selected group of institutional investors, family offices and strategic partners in Canada, the US and internationally. This document does not constitute an offer to sell or solicitation to purchase securities. Forward-looking statements are based on management's current expectations; actual results may differ materially. For complete disclosure, refer to DiagnosTear Technologies Inc. public filings on SEDAR+ (sedarplus.ca). © DiagnosTear Technologies Inc. September 2026.